Spectrum Pharmaceuticals and GPC Biotech Receive Clearance From FDA to Initiate Phase 3 Registrational Trial of Satraplatin Primary Endpoint for Accelerated Approval Will Be Time to Disease Progression Tuesday September 2, 8:00 am ET IRVINE, CA--(MARKET WIRE)--Sep 2, 2003 -- Spectrum

Spectrum Pharmaceuticals Reports Second Quarter Financial Results and Highlights Year-to-Date Progress Monday August 18, 9:00 am ET IRVINE, CA--(MARKET WIRE)--Aug 18, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today reported a net loss for the second quarter ended June 30, 2003 of $1.6

Spectrum Pharmaceuticals and Lannett Company Announce Exclusive Supply and Distribution Agreement for Ciprofloxacin Monday August 18, 9:15 am ET IRVINE, CA--(MARKET WIRE)--Aug 18, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) and Lannett Company, Inc.

Spectrum Pharmaceuticals Completes $3 Million Financing Led by Baystar Capital Thursday August 14, 2:45 pm ET IRVINE, CA--(MARKET WIRE)--Aug 14, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today announced that it has raised approximately $3.0 million through the sale of newly issued

Spectrum Pharmaceuticals to Host Conference Call to Discuss Second Quarter Financial and Operating Results Wednesday August 13, 9:56 am ET IRVINE, CA--(MARKET WIRE)--Aug 13, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC: SPPI) will hold a conference call on Monday, August 18th at 10:30 a.m.

Spectrum Pharmaceuticals' Patent Application on Its Anti-Psychotic Drug Platform Is Published Monday August 11, 10:00 am ET IRVINE, CA--(MARKET WIRE)--Aug 11, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) announced that the U.S. Patent Office has published U.S. Patent Application No.

Spectrum Reports Positive Phase 1 Data; Will Initiate Phase 2 Study of Eoquin(TM) in Superficial Bladder Cancer Wednesday June 11, 10:00 am ET IRVINE, Calif., June 11 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today reported a complete response in each of the first five

Spectrum Pharmaceuticals to Host Conference Call to Discuss Recent Developments in Its Oncology Programs Monday June 9, 9:50 am ET IRVINE, Calif., June 9 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) will hold a conference call on Thursday, June 12th at 10:30 a.m.

Spectrum Pharmaceuticals Reports Positive Clinical Data Presented on Satraplatin in the Treatment of Hormone-Refractory Prostate Cancer at ASCO Satraplatin Achieves Statistically Significant Doubling of Progression-Free Survival Tuesday June 3, 9:07 am ET IRVINE, Calif., June 3

Spectrum Pharmaceuticals Announces Nasdaq Decision to Continue Company's SmallCap Market listing Listing Qualifications Panel Rules That the Company has Regained Compliance With Listing Requirements Monday June 2, 10:24 am ET IRVINE, Calif., June 2 /PRNewswire-FirstCall/ -- Spectrum

Spectrum Pharmaceuticals Nominates Former Pfizer Senior Vice President to Board of Directors Dr. Dilip Mehta Supervised Clinical Trials and New Drug Applications for Blockbuster Drugs Such as Zoloft and Viagra and is Currently an FDA Advisory Committee Member Monday May 19, 5:30 am ET IRVINE,

Spectrum Pharmaceuticals Appoints Julius Vida, Ph.D. to Its Board of Directors Dr. Dilip Mehta Supervised Clinical Trials and New Drug Applications for Blockbuster Drugs Such as Zoloft and Viagra and is Currently an FDA Advisory Committee Member Monday May 19, 5:30 am ET IRVINE, Calif., May 19

Spectrum Pharmaceuticals Receives Additional $1.56 Million in Financing Total of $6 Million Raised During the First Half of May 2003 Wednesday May 14, 5:54 pm ET IRVINE, Calif., May 14 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has raised an

Spectrum Pharmaceuticals' Auditor Removes 'Going Concern' Cautionary Paragraph Based on Completion of Recent Financing Tuesday May 13, 8:35 am ET IRVINE, Calif., May 13 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today reported that based on the Company's successful

Spectrum Pharmaceuticals Announces Trigger of Milestone Payment on FDA Acceptance of Ciprofloxacin ANDA Filing Monday May 12, 8:31 am ET IRVINE, Calif., May 12 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the U.S.

Spectrum Pharmaceuticals Announces FDA Acceptance of ANDA Filing for Ciprofloxacin Friday May 9, 8:31 am ET IRVINE, Calif., May 9 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the US Food and Drug Administration (FDA) has accepted for filing its

Spectrum Pharmaceuticals Completes $4.44 Million Financing With Institutional Investors Thursday May 8, 8:31 am ET IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has raised $4.44 million through the sale of newly issued shares

Spectrum Pharmaceuticals Receives Nasdaq Notice Tuesday April 8, 7:08 pm ET IRVINE, Calif., April 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the Company received a Nasdaq staff determination indicating that the Company is not in compliance with

Spectrum Pharmaceuticals Reports Fourth Quarter and Year End Financials Monday March 31, 8:01 am ET IRVINE, Calif., March 31 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - News ) today reported a net loss for the fourth quarter ended December 31, 2002 of $3.8 million, or

Spectrum Pharmaceuticals to Receive $1 Million Investment Investment to Support Accelerated Development of Spectrum's Generic Drug Business Friday February 7, 8:30 am ET IRVINE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has